✨ Free AI Report
Coya Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Coya Therapeutics, Inc.
Company Research

Coya Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Coya Therapeutics is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation a...

Analyst-debate audio for Coya Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Coya Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Coya's Treg-focused platform addresses multiple high-burden neurodegenerative diseases with limited treatment options, supported...

Read the full analyst-debate transcript →
Industry Clinical-Stage Biotechnology / Specialty Pharmaceuticals - Neurodegenerative Disease Therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Coya Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Coya Therapeutics, Inc. Overview

Pro stress-test →

Coya Therapeutics is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. The company is advancing COYA 302, a biologic combination intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease.

Strategic Profile

Pro stress-test →

The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. In January 2026, the company completed an $11.1 million private placement with Dr. Reddy's Laboratories (a strategic collaborator) investing $10 million.

Competitive Landscape

Pro stress-test →

Coya competes in the neurodegenerative disease space against larger pharma companies and clinical-stage biotech competitors developing for ALS, FTD, and Parkinson's disease. The company's Treg immunology approach is differentiated from conventional small-molecule and monoclonal antibody approaches. Key competitive reference points include other Treg-focused therapies and traditional neurodegenerative disease treatments, though the novel mechanism positions Coya distinctly.

Industry Context

Coya Therapeutics, Inc. operates in Clinical-Stage Biotechnology / Specialty Pharmaceuticals - Neurodegenerative Disease Therapeutics.

Key facts

Founded: 2020 · Headquarters: Houston, Texas

What the analysts stress-tested

The top findings that survived the multi-agent debate for Coya Therapeutics, Inc..

  • Clinical momentum: COYA 302 Phase 2 trial for ALS accepted by FDA in August 2025, with Health Canada CTA clearance in November 2025 expanding geographic reach
  • Positive proof-of-concept: FTD study with low-dose IL-2 and CTLA4-Ig showed clinical benefits in 9 patients, supporting therapeutic hypothesis
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Hosted webinar exploring evolving ALS treatment landscape; CEO letter emphasized strong momentum entering 2026
  • January 2026Announced $11.1M private placement at $4.40/share with Dr. Reddy's and Greenlight Capital participation
  • +1 moreTrack every material event for Coya Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Coya Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Small molecule and antibody therapiesTraditional approaches to ALS and neurodegenerative disease→Cell therapy approachesCompeting cellular immunotherapy platforms→

Compare Coya Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Coya Therapeutics, Inc. operates in Clinical-Stage Biotechnology / Specialty Pharmaceuticals - Neurodegenerative Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Clinical-Stage Biotechnology by Cyborg Score

Browse Clinical-Stage Biotechnology / Specialty Pharmaceuticals - Neurodegenerative Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about Coya Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Coya Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Coya Therapeutics, Inc. do this quarter?”
“Is Coya Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Coya Therapeutics, Inc. do?+
Coya Therapeutics is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation a...
What is Coya Therapeutics, Inc.'s Cyborg Score?+
Coya Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Coya Therapeutics, Inc.'s main competitors?+
Named competitors include Small molecule and antibody therapies, Cell therapy approaches. The full competitive landscape is in the AskCyborg report.
How can I get the full Coya Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Coya Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Coya Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-Stage Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Adaptive Biotechnologies Corporation7Evommune, Inc.7Monte Rosa Therapeutics, Inc.7PepGen Inc.7Tectonic Therapeutic, Inc.6Adlai Nortye Ltd.6Vigil Neuroscience, Inc.5Cel-Sci Corporation4Cassava Sciences, Inc.4INmune Bio Inc.Top companies in Clinical-Stage Biotechnology by Cyborg Score